Genetics
CETP promoter variant -629C>A is strongly linked to cardiovascular disease specifically in Asian Indian patients with type 2 diabetes (J Diabetes Complications 2011)
Original title: The relationship of ACE and CETP gene polymorphisms with cardiovascular disease in a cohort of Asian Indian patients with and those without type 2 diabetes
This study investigated candidate gene polymorphisms in ACE (insertion/deletion, rs4646994) and CETP (-629C>A, rs1800775) for association with cardiovascular disease (CVD) in 520 Asian Indian individuals: 160 with CVD plus type 2 diabetes (T2DM), 90 with CVD without T2DM, 150 with T2DM without cardiovascular complications, and 120 age- and sex-matched healthy controls. The ACE D/D genotype was more frequent in CVD+T2DM patients but not statistically significant, while the CETP -629A allele was significantly associated with CVD+T2DM compared to controls (P=.000007, OR=0.46, 95% CI 0.32-0.65), but not with CVD alone. Additive interactions were identified between CETP AA plus ACE I/I genotypes, CETP AC plus ACE I/D, and CETP AC plus ACE D/D (P=.0052, .0009, and .0078 respectively). The authors conclude the CETP -629C>A polymorphism may serve as a CVD susceptibility biomarker specifically in T2DM patients in this population.
Original abstract
Introduction: Hypertension and dyslipidemia have been associated with cardiovascular disease (CVD). We investigated the association of candidate gene polymorphisms in angiotensin-converting enzyme (ACE) and cholesterol ester transfer protein (CETP) genes in a cohort of Asian Indian patients with and those without type 2 diabetes.
Methods: PCR-based genotyping of insertion/deletion (I/D) polymorphism of ACE (rs4646994) and -629C>A of CETP (rs1800775) was carried out in 520 individuals, of whom 160 had CVD+type 2 diabetes mellitus (T2DM), 90 were CVD patients without T2DM, 150 had T2DM with no cardiovascular complications, and 120 were age- and sex-matched healthy controls.
Results: With respect to the ACE gene I/D polymorphism, there was a higher percentage of D/D genotype in CVD+T2DM patients, but it was not statistically significant, while the CETP -629A allele was significantly associated with CVD+T2DM patients (P=.000007; odds ratio=0.46; 95% confidence interval=0.32-0.65) as compared with the normal controls and not with CVD alone. Additive interactions between the AA+I/I genotypes, AC+I/D genotypes, and AC+D/D were identified between the patients and the controls with P values of .0052, .0009, and .0078, respectively.
Conclusions: Our study suggests that candidate gene polymorphism -629C>A of CETP may serve as a susceptibility biomarker for CVD in T2DM patients. Analyzing the combined effect of both ACE and CETP genotypes would enhance the sensitivity and specificity of CVD risk estimation in the T2DM patients in our population.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.